Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab

Usability of mepolizumab single-use prefilled syringe for patient self-administration

(2019) Elisabeth H. Bel et al.   JOURNAL OF ASTHMA

The role of type 2 innate lymphoid cells in eosinophilic asthma

(2019) Brittany M. Salter et al.   JOURNAL OF LEUKOCYTE BIOLOGY

ERS/TSANZ Task Force Statement on the Management of Reproduction and Pregnancy in Women with Airways Diseases

(2019) Peter G. Middleton et al.   EUROPEAN RESPIRATORY JOURNAL

Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma

(2018) Roma Sehmi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma

(2018) Eugene R. Bleecker et al.   EUROPEAN RESPIRATORY JOURNAL

Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma

(2018) Anurag Bhalla et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

(2018) Sumita Khatri et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

(2018) William W Busse et al.   Lancet Respiratory Medicine

Severe eosinophilic asthma: a roadmap to consensus

(2017) Roland Buhl et al.   EUROPEAN RESPIRATORY JOURNAL

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma

(2017) Maria Gabriella Matera et al.   Expert Opinion on Drug Metabolism & Toxicology

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation

(2017) John Nixon et al.   PHARMACOLOGY & THERAPEUTICS

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials

(2016) Y. Cabon et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma

(2016) R. Sehmi et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

(2016) Njira Lugogo et al.   CLINICAL THERAPEUTICS

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

(2016) Steven G. Smith et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

(2016) Tuyet-Hang Pham et al.   RESPIRATORY MEDICINE

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

(2016) Hector G Ortega et al.   Lancet Respiratory Medicine

Clinical usefulness of mepolizumab in severe eosinophilic asthma

(2016) Francesco Menzella et al.   Therapeutics and Clinical Risk Management

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products

(2015) Liusong Yin et al.   CELLULAR IMMUNOLOGY

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

(2015) Christopher E Brightling et al.   Lancet Respiratory Medicine

High blood eosinophil count is associated with more frequent asthma attacks in asthma patients

(2014) Trung N. Tran et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

(2014) Pranabashis Haldar et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

(2014) Mario Castro et al.   Lancet Respiratory Medicine

High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma

(2014) Robert S. Zeiger et al.   Journal of Allergy and Clinical Immunology-In Practice

Anti-IL5 therapy for asthma and beyond

(2014) Manali Mukherjee et al.   World Allergy Organization Journal

The consequences of not having eosinophils

(2013) G. J. Gleich et al.   ALLERGY

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review: Tissue remodeling and angiogenesis in asthma: the role of the eosinophil

(2008) A.H. Nissim Ben Efraim et al.   Therapeutic Advances in Respiratory Disease